Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have defined cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of chronic kidney disease, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome as well as kidney and myocardial fibrosis.
Mediar Therapeutics Inc. has announced an oversubscribed $76 million series B financing to support its novel anti-fibrotics through clinical studies. The funding will also be used to advance MTX-439 into phase I for the treatment of chronic kidney disease (CKD)-associated fibrosis.
Huayao Jiyuan (Shenzhen) Pharmaceutical Co. Ltd. has described hypoxia inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of cancer, infections, cardiovascular disorders, anemia, chronic kidney disease, disorders of hematopoiesis, inflammatory disorders and acute respiratory distress syndrome (ARDS).
Renal fibrosis represents a key driver of the pathology of chronic kidney disease (CKD), marked by fibroblast activation, tubular damage and inflammation. Previous work found that cyclic guanosine monophosphate (cGMP) levels are markedly reduced in experimental models of renal fibrosis, but the reasons for this decline are not fully understood.
Researchers from the Children’s Hospital of Nanjing Medical University have identified WW domain-containing E3 ubiquitin protein ligase 2 (WWP2) as a key player in the progression from acute kidney injury (AKI) chronic kidney disease (CKD).
The priority BLA from Otsuka Pharmaceutical Co. Ltd., of Tokyo, and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization Inc., for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN) has received accelerated approved by the U.S. FDA.
Q32 Bio Inc. handed off rights to phase II-stage complement inhibitor ADX-097 in a deal with Akebia Therapeutics Inc. that helps the former extend its cash runway to focus on lead candidate bempikibart in alopecia areata and bolsters the latter’s efforts to build a rare kidney disease pipeline.
Eli Lilly & Co. has synthesized relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of pulmonary hypertension, chronic obstructive pulmonary disease, acute kidney disease, chronic kidney disease, diabetic nephropathy and cardiovascular disorders, among others.
The priority BLA from Otsuka Pharmaceutical Co. Ltd., of Tokyo, and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization Inc., for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN) has received accelerated approved by the U.S. FDA.
RSS
